MYC and neoplasm: Additionally, MYC is frequently dysregulated in lung, colorectal, and pancreatic cancers, where its aberrant expression correlates with tumor aggressiveness and treatment resistance (Wallbillich and Lu, 2023; Dhanasekaran et al., 2022; Hessmann et al., 2016).